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Endometriosis is a common, estrogen-dependent disease, in which endometrial tissue grows 
in the peritoneal cavity. These lesions often express low levels of progesterone receptors 
(PR), which potentially play an important role in the insufficient response to progestin 
treatment. Here, we uncover an interconnection between the downregulated PR expression 
and the epithelial-to-mesenchymal transition (EMT) in endometriotic lesions. The majority of 
ectopic epithelial glands (93.1 %, n=72) display heterogeneous states of EMT by 
immunohistochemistry staining. Interestingly, low PR expression associated with high N-
cadherin expression, a hallmark of EMT. In order to gain mechanistic insights, we performed in 
vitro functional assays with the endometriotic epithelial cell lines EM’osis and 12Z. TGF-β-
induced EMT, marked by elevations of CDH2 and SNAI1/2, led to a significant downregulation 
of PR gene expression in both cell lines. In contrast, silencing of SNAI1 in EM’osis and of 
SNAI1 plus SNAI2 in 12Z elevated PR gene expression significantly. We found that not only in 
vitro, but also in the epithelial component of endometriotic lesions strong expression of 








association of the heterogeneous states of EMT and suppressed PR expression in 
endometriotic lesions. Our functional assays indicate that EMT contributes to the 
downregulation of PR expression via the upregulation of EMT-TFs, like SNAI1 and SNAI2, 
which may ultimately lead to therapy resistance. 
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Endometriosis is a common gynecological disease affecting around 6-10 % of women of 
reproductive age, causing pelvic pain and infertility [1]. Characterized by the presence of 
endometrial epithelial and stroma cells outside the uterine cavity, the endometriosis lesion still 
depends on estrogen to grow [2]. Consequently, the basic rationale of the current medical 
therapies for endometriosis is to reduce estrogen level.  
Progestins, known for their anti-estrogenic effects resulting in endometrial decidualization, and 
inhibit the surges of gonadotropin-releasing hormone / luteinizing hormone [3, 4] and thereby 
block the ovulation. They also locally reduce estrogenic effects by stimulating the transcription 
of the enzyme 17β-HSD2 [5], which catalyzes the conversion of the highly active estrogen 
estradiol (E2) to less potent estrone. Thus, progestins can suppress the endometrial 
proliferation and induce apoptosis, consequently, impeding the proliferation of the 
endometriosis lesions. However, the treatment failure for endometriosis patients under 
progestin-based therapy is increasingly noticed, potentially involving an attenuated response 
to progestin treatments termed progesterone resistance [6, 7]. Progestins exert their effects by 
binding to progesterone receptors (PR). Suppressed PR expression has been preferentially 
reported in ectopic lesions [8, 9]. Several reports indicated that PR reduction could impede the 
progestin therapy response [6, 10, 11]. However, the mechanisms leading to the reduced PR 
expression in endometriosis remain largely unknown. Comprehensive studies and reviews 
suggested that the downregulation of PR may be a consequence of the exposure to an altered 
peritoneal cavity microenvironment [7, 12, 13]. It is important to understand the specific 
mechanisms which may cause loss of PR expression and whether it contributes to the 
resistance to progestin therapy. 
Epithelial-mesenchymal transition (EMT) is a biological process during which epithelial cells 
lose the epithelial features and instead gain properties of mesenchymal cells. The hallmark of 
EMT is the so-called “Cadherin switch”, marked by downregulation of E-cadherin and 
upregulation of N-cadherin [14-16]. E-cadherin is the epithelial marker, which supports 
columnar morphology, bud outgrowth and luminal structure [15, 16]. N-cadherin is the 
mesenchymal marker, which was reported to promote aggregation and collective cell migration 
that facilitates invasion and metastasis [14]. A number of studies reported EMT-inducing 
transcription factors (EMT-TFs) to promote the EMT process through various signaling 
cascades [17-19]. Examples for such EMT-TFs are Snail family transcriptional repressor 
1 (SNAI1), Snail family transcriptional repressor 2 (SNAI2, also known as slug), and Zinc 









investigation of these tissue-specific EMT-TFs and their pleiotropic roles in physiological and 
pathological conditions [18, 21]. Particularly in endometriosis, EMT related processes were 
significantly upregulated in ectopic endometrial lesions compared to eutopic endometrium [22, 
23]. Therefore, EMT might participate in the pathogenesis of endometriosis [24]. EMT can be 
induced by various growth and differentiation factors. Among those, TGF-β is recognized as a 
major inducer of EMT, which increases the transcription factors SNAI1/2 and ZEB1/2 through 
a well-orchestrated transcription program [25, 26]. Interestingly, an increased TGF-β 
concentrations have been frequently observed in endometriosis patients in peritoneum and 
peritoneal fluid surrounding endometriosis tissues [27, 28].  
 
To our knowledge, there are no studies that investigated EMT as the potential cause for the 
downregulation of progesterone receptors in endometriosis lesions. Hence, the purpose of this 
study was to investigate the association between PR expression and EMT in endometriosis 









2. Materials and Methods: 
2.1. Patient tissue handling 
All endometriosis ectopic lesions have been collected following a protocol approved by the 
local ethical committee. The lesions were categorized as superficial peritoneal endometriosis 
(SUP), endometrioma (OMA) or deeply infiltrating endometriosis (DIE). The diagnosis of 
endometriosis was confirmed by pathologists. Menstrual cycle, potential hormonal treatment, 
endometriosis subtypes and number of identified glands were summarized in the 
supplementary Table 2. Samples fixed with formalin were stored in 70 % ethanol at 4 °C 
before proceeding to paraffin embedding.  
 
2.2. Immunohistochemistry (IHC) and immunofluorescence (IF) 
Paraffin embedded tissues serially dissected into 4 µm sections. The antibodies are listed in 
supplementary Table 1. 
IHC was performed as previously described by Flores et al. [11]. After antigen retrieval at 
95 °C in citrate buffer (pH=6) for 8 min, paraffin sections were cooled to room temperature 
(RT) and washed 3 times in Tris-buffered saline (TBS). Each section was incubated in 
hydrogen peroxide solution (3 %) for 10 min. After washing 3 times in TBS-0.25 %Tween 
(TBST), blocking buffer (X0909, DAKO, Denmark) was applied to sections for 1h. Tissue 
sections were incubated with primary antibodies for N-cadherin, E-cadherin, and progesterone 
receptors (PR) overnight at 4 °C. Sections were subsequently incubated with biotinylated 
secondary antibodies at RT for 1 h the next day. The sections were incubated in 
diaminobenzidine (DAB, D3939, Sigma-Aldrich, USA) for 1-4 min following 30 min 
streptavidin-horseradish peroxidase (ab7403, Abcam, USA) incubation and removal. 
Hematoxylin was applied as counterstaining. 
For IF, the tissue sections were at 95 °C in citrate buffer (pH=6) for 15 min for antigen 
retrieval. Then they were incubated with the primary antibodies overnight at 4 °C and the 
fluorophore-conjugated secondary antibodies were incubated at RT for 1 h. The cell nuclei 
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, D9564, Sigma-Aldrich, USA).  
As the negative controls, ectopic tissue samples were incubated with blocking buffer with 3 % 
goat serum instead of primary antibodies. 
Panoramic scanner (250 Flash II, 3DHISTECH) was used for capturing the pictures from IF 
and IHC. QuPath (version 2.2) was used for detecting the positive and negative cells 
according to the uniformed thresholds, and for capturing the fluorescence intensities. All of the 
ectopic epithelial glands were identified and the percentage of positive cells per gland was 
calculated accordingly. 
 








12Z and EM’osis cell lines were both obtained in January of 2013 as the generous gifts from 
collaborating labs [29, 30]. Both cell lines were passaged in IMDM supplemented with 10 % 
FCS. 12Z at passage 50-51 of and EM’osis at passage 14-15 were used in our experiments. 
These cells were negative for mycoplasma infection (MycoAlert, Lonza, Switzerland). 
Transforming growth factor beta1 (TGF-β1, AF-100-21C, Peprotech) was prepared in PBS and 
SB431542 (1614, TOCRIS), a selective inhibitor of TGF-β1 receptor in DMSO. Cells were 
cultured in 6-well plate in phenol red-free IMDM supplemented with 5 % charcoal-stripped FBS 
(A33821-1, Gibco) at the density of 2x105 cells per well for 12Z and EM’osis until 70-80 % 
confluence. To determine the IC50 of TGF-β1, cells were treated in triplicates with doses 
ranging from 0.125 to 1 ng/ml. The involvement of TGF-β1 receptor was assessed with a co-
treatment of TGF-β1 (0.5-1 ng/ml) and SB431542 (100 nM). Control groups were treated with 
an equivalent volume of vehicles. The cells were harvested after 24h treatment by 
trypsinization and RNA isolated as described below. All cell cultures were maintained at 37 °C 
in a 5 % CO2 atmosphere. 
 
2.4. Quantitative Real-Time-Polymerase chain reaction (qRT-PCR) 
RNA extraction was performed with the ReliaPrep™ RNA Miniprep Systems (Z6011, 
Promega, USA) according to the manufacturer’s instructions. One microgram of RNA was 
reverse transcribed in a final volume of 20 µl with RNase inhibitor (N261A, Promega, USA), 
reverse transcriptase enzyme (M1708, Promega, USA), nucleotide mix (U1518, Promega, 
USA), and random primers (C118A, Promega, USA). The resulting cDNA was diluted 1:10. 
Real-time quantitative polymerase chain reaction (qRT-PCR) using Taqman Fast advanced 
Master Mix (4444556 Thermofisher, USA) and TaqMan® gene expression arrays for PGR 
(gene encoding PR, Hs01556702 m1), CDH2 (gene encoding N-cadherin, Hs00983056 m1), 
SNAI1 (Hs00195591 m1), SNAI2 (Hs0000161904 m1), and ZEB1 (Hs00232783 m1). The 
qRT-PCR was performed on an Applied Biosystems 7500 fast instrument (Thermofisher, 
USA), with the following conditions: 95 ◦C for 5 min, followed by 40 cycles of 95 °C for 5 
seconds and 60 °C for 10 seconds. Multiple reference genes [18S rRNA (Hs99999901_s1), 
GAPDH (Hs00266705_g1), beta-actin(Hs01060665_g1), YWHAZ (Hs 03044281_g1), UBC 
(Hs00824723_m1)] were determined the M value of geNorm by Qbase plus software 
(Biogazelle, Belgium) to compare their stability across the cell lines with/without TGF-β1 
treatments. Considering the expression level, YWHAZ, one of the most stable reference genes 
was employed for normalization among the employed cell types and conditions 
(supplementary  Fig. 1). The comparative cycle threshold (2-∆∆Ct) method was used to assess 
changes in gene expression.  
 









EM’osis was transfected with 20 nM of siRNA against SNAI1 (s13185, Silencer Select siRNA, 
Ambion Inc., USA) or scrambled control siRNA (4390844, Silencer Select Negative Control #1 
siRNA, Ambion Inc., USA). 12Z cells were transfected with 20 nM of a pool of equal proportion 
of 3 siRNA against SNAI1 (SR304489, Human siRNA Oligo Duplex, Locus ID 6615, Origene, 
USA), as well as SNAI2 (Silencer siRNA ID 106954, Ambion Inc., USA) or scrambled control 
from the same set of si-SNAI1 (SR304489, Human siRNA Oligo Duplex, Locus ID 6615, 
Origene USA). One µl lipofectamine RNAiMAX as transfection reagent (13778075, 
Thermofisher, USA) was used for one well of 24-well plate under 80 % confluent cells, 
according to vendor’s instructions. RNA was isolated 48h after transfection. 
 
2.6. Statistical Analysis 
All statistical analyses were performed in Graphpad Prism version 8.0. Mann-Whitney test was 
used when the data were not normally distributed, i. e. to compare PR expression between N-
cadherin positive/negative groups. One-way ANOVA was used to identify the difference of 
gene expression between different treatment groups in the in vitro models. P <0.05 was 











3.1. Various EMT states can be detected within ectopic lesions 
The protein expressions of E-cadherin and N-cadherin in ectopic epithelial cells was quantified 
by IHC in three subtypes of endometriosis: endometrioma (n = 4), superficial endometriosis (n 
= 3) and deeply infiltrating endometriosis (n = 4). From these 11 cases a total of 72 epithelial 
glands were characterized and their profiles are summarized in supplementary Table 2. 
Interestingly, most of the analyzed ectopic glands displayed various states of EMT, 
characterized by either reduced E-cadherin and/or increased N-cadherin expression (Fig. 1). 
Only a small fraction of the glands (5/72, 6.9 %) contained exclusively differentiated epithelial 
cells (100 % E-cadherin and 0 % N-cadherin positive cells) (Fig. 1B).  
 
3.2. High N-cadherin at protein expression is concurrent with low protein PR expression at 
in ectopic lesions 
IHC staining of serial sections revealed a rather low and heterogeneous protein expression of 
PR with a median of 10.5 % PR positive epithelial cells per gland. Due to the impact of 
hormone on PR expression, only the cases without hormonal treatment were considered in 
further analysis. Within this population (non-hormone users, n = 6; glands, n = 50, 
Supplementary Table 2), we observed that PR expression was significantly lower in N-
cadherin positive epithelial glands compared to that in N-cadherin negative epithelial glands 
(median 0.00 vs 12.09, P = 0.028, Fig. 2A). This negative association is illustrated in the 
representative immunostaining shown in Fig. 2B and 2C, where PR expression was stronger 
in the epithelial cells with lower N-cadherin expression. Immunofluorescence staining of 
ectopic lesions confirms that the expression of N-cadherin and PR is distributed in a mutually 
exclusive manner in ectopic glands (Fig. 2D-G). 
 
3.3. EMT inducing transcription factors inhibit PGR gene expression in vitro 
We next investigated how the induced EMT alters the PGR gene expression. The TGF-β 
pathway plays a crucial role in the induction of EMT in endometriosis and other model systems 
[24, 25]. When applied to ectopic epithelial derived cell lines (12Z and EM’osis), TGF-β1 
indeed increased the expression of CDH2 and SNAI1, both hallmarks for EMT, in a dose 
depend manner (Fig. 3A and 3B). In EM’osis cells, CDH2 expression was only minimally 
altered, most likely due to its mesenchymal status characterized by a high expression level of 









lesion, PGR gene expression is decreased following TGF-β1 induced EMT. The 
downregulation of PGR under 24-hour TGF-β1 treatment is statistically significant in EM’osis 
and 12Z cells (P<0.05). As expected, TGF-β1 receptor inhibitor abrogated the TGF-β1 induced 
downregulation of PGR, and even upregulated PGR significantly in EM’osis cells (P<0.001) 
(Fig. 3C and 3D). SNAI1 was increased by TGF-β1 treatment significantly in both cell lines 
(P<0.001). In addition, SNAI2 upregulation under TGF-β1 treatment was only observed in the 
12Z cell line (P<0.05). ZEB1, another core EMT promoting TF, did not increase under TGF-β1 
treatment in either cell line (Fig. 3C and 3D). 
    
3.4. EMT related PGR repression is SNAI1/2 dependent 
12Z and EM’osis cells were transfected with siRNA targeting SNAI1 and SNAI2 to evaluate the 
role of these TFs in the EMT dependent suppression of PGR. In EM’osis cells, knockdown of 
SNAI1 reaching 58.7 % reduction at 48 h after transfection, resulted in a significant increase of 
PGR expression (1.26 fold, P = 0.028, Fig. 4A). In 12Z cells, a combined knockdown of SNAI1 
and SNAI2 was used, since both factors increased after TGF-β1 treatment (Fig. 4B). The use 
of this siRNA mixture (siRNA against SNAI1 and siRNA against SNAI2) was also supported by 
the fact that a compensatory mechanism apparently takes place when SNAI1 or 2 are 
downregulated independently (supplementary Fig. 3). Indeed, SNAI2 downregulation led 
surprisingly to an increase of SNAI1 mRNA expression (and vice versa) in 12Z (supplementary 
Fig. 3). Hence, the siRNA mixture represented the most efficient way to keep both SNAI1 and 
2 at low levels. In fact, in 12Z, the combined knockdown decreased by 48.6 % the mRNA level 
of SNAI2 while preventing the expected increase of SNAI1 (siSNAI1+2, Fig. 4B). All in all, 
SNAI silencing in 12Z led to a significant elevation of PGR expression (1.39 fold, P = 0.0002, 
Fig. 4B), as found in EM’osis cells.  
Next, we performed an in silico analysis of the PGR to identify a possible cause for our 
observed downregulation of the PGR at mRNA level. This analysis revealed 8 potential cis–
acting elements (CANNTG, E-box) for both SNAI1 and SNAI2, listed in supplementary Table 
3. Altogether, these in vitro experiments demonstrated that TGF-β1 induced EMT, 
characterized by an increase of mesenchymal markers (CDH2 and SNAI1/2), importantly, is 
accompanied by SNAI dependent PGR downregulation. 
3.5. SNAI1/2 and PR expressions are negatively correlated in DIE ectopic lesions 
We further verified the protein expression level of SNAI1/2 in ectopic lesions by IF (Fig. 4C, 









cells associates with the low protein expression of PR, while the low protein expression of 
SNAI1/2 was concurrent with the high protein expression of PR.  
And we further used Qupath to detect the intensity of immunofluorescence signals of SNAI1/2 
and PR from 647 epithelial cells from 6 ectopic glands from 3 DIE lesions. The negative 
correlation of protein expressions of SNAI1/2 and PR was indicated by the correlation analysis 
(r = -0.12, P = 0.0024). Hence, our study confirmed SNAI1/2 play an important role to regulate 
PR not only limited in vitro but also in vivo in patients with DIE. 
 
4. Discussion 
Our study revealed a potential negative association between PR and N-cadherin at the protein 
level. By employing endometriotic cell lines, we verified that TGF-β1-induced EMT 
downregulated PGR gene expression. Furthermore, we found that SNAI1/2, two core EMT-
TFs, play the important roles in regulation of PGR. Most importantly, the results were 
supported in situ, showing a negative correlation between SNAI1/2 and PR protein expression 
in endometriosis lesions. 
We observed that PR was absent in the individual endometriotic epithelial cells, which was 
widely mentioned previously by multiple studies [8, 9, 11, 31]. Using the open-source software 
QuPath that automatically quantified the staining intensity of individual cells from the 
immunohistochemistry, we calculated the percentage of positive cells per epithelial gland. A 
representative example of the QuPath analysis is shown in supplementary  Fig. 2. Interestingly 
and importantly, the expression of PR is heterogeneous intrasubject. This finding is consistent 
with a recent report [11]. Due to the limited sample size, we refrained from performing a 
subgroup analysis on PR expression across different endometriosis subtypes. 
Meanwhile, immunohistochemistry revealed that most of the ectopic glands lose E-cadherin 
expression (n = 48/72) and partially expressing N-cadherin (n = 18/72). In agreement with a 
previous report, these partial EMT states are present in most ectopic epithelial glands, being 
likely triggered by the altered pelvic microenvironment [32]. We further found out the PR 
expression was significantly lower in N-cadherin positive epithelial glands compared to that in 
N-cadherin negative epithelial glands (Fig. 2 A). The low PR expression is concurrent with high 
N-cadherin expression, illustrated in immunofluorescence co-staining of PR and N-cadherin 
(Fig. 2 D-G). This is in line with a previous report from Liu et al, who found that PR-B, a 
dominant isoform of PR in endometrium, negatively correlated with EMT markers in 









Our hypothesis that EMT contributes to PR downregulation in endometriosis was inspired by a 
report on endometrial cancer, which explored the reversion of progesterone resistance by 
suppressing EMT in Ishikawa cells [34]. However, the alterations of PR expression under EMT 
and reversed EMT were not reported in that study. Hence, to the best of our knowledge, this is 
the first study reporting a contribution of EMT in the regulation of PR expression in 
endometriosis. Our study not only revealed this regulation in another system, but also 
identifies underlying mechanisms. 
We verified the regulation of PGR via a TGF-β1 induced EMT in endometriosis derived cell 
lines. In the endometriotic epithelial cells, 12Z and EM’osis, TGF-β1-induced EMT altered 
PGR expression in a dose dependent manner. The same effect was also observed in Ishikawa 
cells (data not shown). The downregulation of PGR by TGF-β1 treatment was previously 
reported in two independent studies [35, 36]. These studies were limited to stromal cells from 
endometriosis. And importantly, the link between TGF-β1 and EMT as well as EMT related 
pathways has not been suggested in either study. 
TGF-β1-induced EMT was characterized by the increase of the mesenchymal marker CDH2 
and the EMT-TFs SNAI1/2 in 12Z and EM’osis and ZEB1 in Ishikawa cells (data not shown). 
We identified SNAI1 and SNAI2 as the most affected TFs during TGF-β1-induced EMT in 
endometriotic cells in vitro. One previous study [37] reported that both TGF-β1 and SNAI1 
were expressed strongly in ectopic epithelial cells compared to eutopic endometrium, 
supporting our results from the in vitro model. Strikingly, we noticed that different TFs were 
activated in a cell-specific manner in our in vitro model of TGF-β1-induced EMT, which is 
consistent with prior knowledge of the tissue-specific activities of these TFs [18, 38]. 
Interestingly, in 12Z cells SNAI1 and SNAI2 compensated each other, which means 
knockdown SNAI2 leads to a sharp increase of SNAI1, and vice versa as shown in 
supplementary  Fig. 3. This reciprocal expression of SNAI1 and SNAI2 was previously found in 
oral cancer cells [39]. Furthermore, SNAI1 and SNAI2 recognized as transcriptional 
repressors, share a common organization, and specifically both contain SNAG which is 
important for the repressor capacity of SNAI factors [19]. Therefore, even though SNAI1 is not 
downregulated in knock-down experiment in 12Z cells, the efficient downregulation of SNAI2 
still leads to an elevation of PGR. 
In line with other reports [40-42], knockdown of SNAI1 by siRNA in EM’osis cell lines was only 
moderately efficient, but nevertheless resulted in a consistent upregulation of PGR. These 
results suggest that SNA1/2 mediate EMT, which induces PGR repression either by acting 









repress gene expression by binding to its motif constituting a subset of E-box [43]. 
Interestingly, each PR promoter contains four E-box motifs. Thus, it is plausible to postulate 
that SNAI1/2 suppresses PGR transcription by binding to the gene promoters. 
As the difficulty of setting up culture condition for primary epithelial cells, we employed 
immortalized endometriotic epithelial cell lines, 12Z and EM’osis. However, we observed both 
cell lines have lost their epithelial phenotype in culture, especially EM’osis cells. They showed 
a typical mesenchymal phenotype under the microscope, recognizable by a spindle like shape. 
The protein expression of E-cadherin was not detectable, instead N-cadherin was strongly 
expressed as previously reported for 12Z [30]. PR expressions at protein level in both cell lines 
are also not detectable, which are possibly natural results due to the mesenchymal status. In 
another hand, our study conclusions have been therefore restricted to the transcriptomic level. 
However, the negative correlation between SNAI1/2 and PR could be confirmed by 
immunofluorescent double staining in patient samples. This is in line with the strong protein 
expression of SNAI in ectopic lesions [37, 44, 45]. 
 
5. Conclusions and outlook 
Our study indicates that the clinically relevant, but so far unrevealed downregulation of PR 
could be the consequence of the heterogeneous EMT states in endometriosis lesions. Since 
the altered PR expression in ectopic lesions might indicate the attenuated response to 
progestin-based therapy, we propose that EMT participates in progestin treatment resistance 
and/or failure. In our study, SNAI1/2 silencing concurrently reversed EMT and increased PGR 
expression. This highlights the potential role of EMT related factors in the downregulation of 
PGR. Ultimately, it will be interesting to explore the effect of relevant compounds, such as 
SNAI inhibitors, to reverse EMT in endometriosis. This might lead to the establishment of a 
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Fig. 1 Ectopic lesions reveal heterogeneous EMT states (A) A heatmap representing the gradual reduction of E-
cadherin (left column) in ectopic glands from non-hormone users (Patients, n = 6; SUP glands, n = 3, OMA glands, 
n = 9 and DIE glands, n = 38) and hormone users (Patients, n = 5; SUP glands, n = 1, OMA glands, n = 2 and DIE 
glands, n = 19) and concurrently with, or without, N-cadherin expression (right column). The percentage of cells 
positive for E-cadherin or N-cadherin per glands is illustrated by the color code shown on the right side. The 
numbers in the left panel represent the identification for each single gland (n = 72). (B) E-cadherin and N-cadherin 
expression per ectopic gland as unit were classified into 100 %, 1-99 %, and 0 %. Seventy-two glands were 
categorized accordingly. (C, D) Immunohistochemical stains for E-cadherin and N-cadherin in serial sections of 
ectopic tissues representing the two main subgroups highlighted in B. Percentages of positive cells per single gland 









Fig. 2 N-cadherin expression negatively correlates with PR expression (A) PR protein expression level was 
lower in N-cadherin positive glands than in N-cadherin negative glands amongst the non-hormone users 
(Patients n = 6; SUP glands n = 3; OMA glands n = 9; and DIE glands n = 38) (P=0.0028, by Mann-Whitney test, 
data are presented as median with range). (B, C) Representative immunochemistry staining illustrated the 
mutually exclusive N-cadherin and PR expression in ectopic glands (magnification 600x). (D-G) 
Immunofluorescent double staining illustrated the differential expression of N-cadherin (in green) and PR (in 















































































































































































Fig. 3 TGF-β1 dose-dependent changes of  gene expression in endometriotic epithelial cell lines (A) EM’osis 
cells and (B) 12Z cells were treated in triplicates with TGF-β1 (0.125, 0.25, 0.5, 0.75, 1 ng/ml) for 24 h. 
Values are presented by mean  SEM of one representative experiment. (C) Expression of CDH2, PGR, 
and EMT related TFs (ZEB1, SNAI1 and SNAI2) in EM’osis cells treated in four independent experiments 
with TGF-β1 (1 ng/ml) and TGF-β1 inhibitor (100 nM) for 24 h. Control group were under the equivalent 
volume of vehicles. (D) Expression of CDH2, PGR, and EMT related TFs (ZEB1, SNAI1 and SNAI2) in 12Z 
cells treated in four independent experiments with TGF-β1 (0.5 ng/ml) and TGF-β1 inhibitor (100 nM) for 
24 h. Values are presented as mean  SEM and P values were calculated by one-way ANOVA test. * 











Supplementary table 1: Antibodies applied in immunohistochemistry and immunofluorescence 
Supplementary tables: 
Fig. 4 EMT related PR repression is SNAI-dependent (A) Silencing SNAI1 in EM’osis cells was done by transfection of 
siRNA against SNAI1/2 (20 nM) in triplicates in two independent experiments. Transfections with the same amount of 
scrambled siRNA, and untreated cells were used as controls. (B) Silencing SNAI1/2 in 12Z cells was performed in 
triplicates in two independent experiments, using the pooled SNAI1/2 with 2:1 ratio of si-SNAI1 and si-SNAI2. 
Controls were the same a  for EM’osis cells. (A, B) Values are presented as mean  SEM and P values were 
calculated by one-way ANOVA test. * P<0.05, **P<0.001, “ns” stands for non-significant. (C-F) Representative 
staining of SNAI1/2 (green) was shown in part of epithelial component, and the representative staining of PR 
(red) in ectopic epithelial glands (magnification 400x). The grey scale bars represent 50 µm.. (G) Correlation 
analysis on the intensity of fluorescence for SNAI1/2 and PR in epithelial cells. DIE lesions were co-stained with 









Supplementary Table 1: Antibodies applied in immunohistochemistry and 
immunofluorescence  
Antibody Vendor name 
and Catalog 
number  



























Dako (Agilent)  
Cat# M3612 
 







































































































Supplementary Table 2: Patient profiles for ectopic lesions 









and Glands numbers 
1 35 24.6 NA IV Zoladex DIE 
N-cadherin+  12 
N-cadherin-   2 
2 48 29 Proliferative IV None DIE 
N-cadherin+  8 
N-cadherin-   26 
3 33 23.3 Proliferative II 
Progynova. 
Cream 5 % 
DIE 
N-cadherin+  2 
N-cadherin-   3 
4 36 20.4 Proliferative IV None DIE 
N-cadherin+  4 
N-cadherin-   0 
5 30 22.9 NA IV Visanne OMA 
N-cadherin+  1 
N-cadherin-   0 
6 32 25 NA IV Visanne OMA 
N-cadherin+  0 
N-cadherin-   1 
7 30 19.9 Proliferative IV None OMA 
N-cadherin+  0 
N-cadherin-   5 
8 37 24.1 Proliferative IV None OMA 
N-cadherin+  1 
N-cadherin-   3 
9 35 24 NA I Visanne SUP 
N-cadherin+  0 
N-cadherin-   1 
10 34 19.9 Secretory IV None SUP 
N-cadherin+  0 
N-cadherin-   2 
11 38 25 Proliferative IV None SUP 
N-cadherin+  0 
N-cadherin-   1 
DIE: Deeply infiltrative endometriosis; OMA: Endometrioma; SUP: Superficial peritoneal 
endometriosis. “N-cadherin+” stands for >0 % of N-cadherin positive epithelial cells per gland. 











Supplementary  Fig. 1 A, B Variations of reference genes in studied cell lines 
 
 
TaqMan® gene expression arrays for five reference genes 18S, b-actin, GAPDH, YWHAZ and 
UBC were performed across the different cells 12Z (A) and EM’osis (B) under TGF-β1 
treatment (1 ng/ml, 6 h) Representative experiment performed in triplicates. Qubase+ was 










Supplementary  Fig. 2 IHC staining and analysis of PR with QuPath 
 
IHC staining and analysis for PR. The percentage of positive cells was calculated using the 
automatic cell detection in QuPath. Firstly, the gland structure needs to be selected as a unit 
(yellow outline). Subsequently, the cells are identified by the optical density, immunostained 
cells are detected according to a predefined threshold. As a result, the cells positive for PR 
expression are outlined in red and the cells considerd negative expression are outlined in blue. 
In this gland, 63 % of cells were characterized as positive for PR expression. Scale bar 
represents for 20 µm. 
 
 
Supplementary  Fig. 3 Silencing of SNAI1 and SNAI2 in 12Z cells 
 
12Z cells were transfected with si-SNAI1, si-SNAI2, and pooled si-SNAI1/2 with 2:1 ratio in 
triplicates. The transfection with the same amount of scrambled siRNA, and untreated cells 

















































Supplementary Table 3 : Potential SNAIL binding sites on PGR promoters 
Sequences for PR-B and PR-A refer to Kastner et al [46]. Sequences for PR-B promoter 
located between -711 to +31 in Chromosome 11 101000514-101001255. Sequences for PR-A 
promoter located between +464 to +1105 in Chromosome 11 100999436-101000085. 
Sequences marked in red represent E-box motifs of SNAI binding sites. 
 





























































































































Supplementary  Fig. 4 
 
IHC controls. A and B are E-cadherin positive and negative controls respectively, in eutopic 
endometrium. C and D are N-cadherin positive and negative controls respectively, in ectopic lesions. E 
and F are Progesterone receptor positive and negative controls respectively, in tissue of eutopic 
endometrium. G and H are SNAI1/2 positive and negative controls respectively, in ectopic lesions. 
Scale bar stands for 50 µm. 
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